LKC Technologies Inc is a biotechnology and medical device company primarily focused in the visual electrophysiology field. The firm has created a low-priced, handheld diabetic retinopathy (DR) screening device, called RETeval, to enable virtually any health care provider to screen for and detect sight-threatening DR, the leading cause of working age blindness worldwide. RETeval is a functional test of the retina to assess the ischemic level of the retina, which correlates well to DR and other ischemic diseases such as Central Retinal Vein Occlusion, Birdshot and others. The low price allows health care providers, from physicians' offices to community clinics to mobile clinics in third-world countries, to easily use the RETeval and be highly effective in alerting patients to their risk of diabetic retinopathy. The Centers for Disease Control estimates that better DR detection can reduce blindness by 50-60%.
